Comparison of Clinicopathologic Characteristics of Urothelial Carcinoma Between Patients After Renal Transplantation and on Dialysis
暂无分享,去创建一个
W. Han | Cheng Shen | Bo Zhang | Wei Yu
[1] A. Francés,et al. Bladder transitional cell carcinoma and BK virus in a young kidney transplant recipient , 2013, Transplant infectious disease : an official journal of the Transplantation Society.
[2] Pau-Chung Chen,et al. Occupational exposure to herbs containing aristolochic acids increases the risk of urothelial carcinoma in Chinese herbalists. , 2013, The Journal of urology.
[3] D. Rix,et al. The management of transitional cell carcinoma (TCC) in a European regional renal transplant population , 2012, BJU international.
[4] Y. Chiang,et al. Urothelial cancer after renal transplantation: an update. , 2012, Transplantation proceedings.
[5] T. Fang,et al. Increased risk of cancer in chronic dialysis patients: a population-based cohort study in Taiwan. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] K. Shu,et al. Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin. , 2012, Urologic oncology.
[7] D. Toncheva,et al. Urothelial carcinoma associated with Balkan endemic nephropathy. A worldwide disease. , 2011, Pathologie-biologie.
[8] Y. Zhu,et al. Association between urothelial carcinoma after renal transplantation and infection by human papillomavirus types 16 and 18. , 2011, Transplantation proceedings.
[9] Pau-Chung Chen,et al. Increased risks of upper tract urothelial carcinoma in male and female chinese herbalists. , 2011, Journal of the Formosan Medical Association = Taiwan yi zhi.
[10] S. Melchior,et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. , 2011, The Journal of urology.
[11] P. Chiang,et al. Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up. , 2010, Japanese journal of clinical oncology.
[12] A. Webster,et al. The pattern of excess cancer in dialysis and transplantation. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[13] S. Chueh,et al. Sirolimus does not absolutely abolish the occurrence/recurrence of urothelial carcinoma in renal transplant recipients. , 2008, Transplantation proceedings.
[14] M. Fischereder. Cancer in patients on dialysis and after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] Y. Hsueh,et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study , 2008, Cancer Causes & Control.
[16] C. Decaestecker,et al. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] J. Nortier,et al. For patients taking herbal therapy--lessons from aristolochic acid nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[18] Y. Ko,et al. Malignancies after renal transplantation in southern Taiwan: experience in one centre , 2007, BJU international.
[19] J. D. van der Walt,et al. Regression of post‐transplant Kaposi's sarcoma using sirolimus , 2006, International journal of clinical practice.
[20] M. Sever,et al. Health-related quality of life after kidney transplantation in comparison intermittent hemodialysis, peritoneal dialysis, and normal controls. , 2006, Transplantation proceedings.
[21] Chi-hung Cheng,et al. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] M. Meng,et al. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. , 2004, The Journal of urology.
[23] R. Oberbauer,et al. Health and Quality of Life Outcomes Health-related Quality of Life Outcomes after Kidney Transplantation , 2004 .
[24] J. Nortier,et al. Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). , 2002, Toxicology.
[25] Yen-Ta Chen,et al. The outcome of post‐transplant transitional cell carcinoma in 10 renal transplant recipients , 2002, Clinical transplantation.
[26] P. Vereerstraeten,et al. Progression rate of Chinese herb nephropathy: impact of Aristolochia fangchi ingested dose. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] D. Nicol,et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. , 2000, Transplantation.
[28] T. Tzai,et al. Transitional Cell Carcinoma in Dialysis Patients , 2000, European Urology.
[29] D. Nicol,et al. Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. , 1998, British journal of urology.
[30] E. Will,et al. Risk of neoplasia in renal transplant patients , 1995, The Lancet.
[31] S. Chu,et al. Urologic cancers in uremic patients. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[32] C. Chuang,et al. Malignancy in renal transplant recipients. , 1992, Transplantation proceedings.
[33] D. McCance,et al. Development of bladder tumour containing HPV type 11 DNA after renal transplantation. , 1988, British journal of urology.
[34] EINZ,et al. UROTHELIAL CARCINOMA ASSOCIATED WITH THE USE OF A CHINESE HERB ( ARISTOLOCHIA FANGCHI ) , 2022 .